

Erratum to: Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir

Todd T. Brown,¹ Carlee Moser,² Judith S. Currier,³ Heather J. Ribaud,² Jennifer Rothenberg,⁵ Theodoros Kelesidis,³ Otto Yang,³ Michael P. Dubé,⁴ Robert L. Murphy,⁶ James H. Stein,⁷ and Grace A. McComsey,⁸

¹Johns Hopkins University, Baltimore, Maryland; ²Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts; ³David Geffen School of Medicine, University of California–Los Angeles, and ⁴Keck School of Medicine, University of Southern California, Los Angeles, California; ⁵Social and Scientific Systems, Washington D.C.; ⁶Feinberg School of Medicine, Northwestern University, Chicago, Illinois; ⁷University of Wisconsin School of Medicine and Public Health, Madison; and ⁸Case Western Reserve University School of Medicine, Cleveland, Ohio

In “Changes in Bone Mineral Density after Antiretroviral Initiation with Tenofovir Disoproxil Fumarate-Emtricitabine plus Atazanavir-Ritonavir, Darunavir-Ritonavir, or Raltegravir [J Infect Dis. 2015 Oct 15;212(8):1241–9.] by Brown et al. there are three errors noted by the authors:

Lines 176–180 Corrected sentence should read:

The following monocyte cell phenotypes were characterized and expressed as percentages: classical phenotype (CD14+CD16-), intermediate phenotype (CD14+CD16+), non-classical phenotype (CD14dimCD16+), CD4+ and CD8+ T cells with activated (HLA-DR+CD38+), senescent (CD28-CD57+) or senescent and exhausted (CD28-CD57+PD1+) phenotypes were assessed.

Lines 279–282 Corrected sentence should read:

Associations of monocyte subpopulations (% MNC: CD14+CD16+, % MNC: CD14dimCD16+) with bone loss at either the lumbar spine or the total hip or were also not consistently detected (data not shown).

Table 1:

Deleted the 2 rows that show data related to: % MNC: CD14 (hi) CD16 (hi) and % MNC: CD14 (low)CD16 (hi). Replaced with 2 new rows that show data related to: % MNC: CD14dimCD16+ and % MNC: CD14+CD16+. The corrected table is reproduced below.

The authors regret these errors.

Table 1. Subject Characteristics at Baseline

| | ATV/r (n=109) | RAL (n=106) | DRV/r (n=113) |
|-----------------------------------------|---------------------|---------------------|---------------------|
| Age (y) | 37 (31,45) | 36 (27,44) | 35 (27,46) |
| Sex | 91% M, 9% F | 89% M, 11% F | 89% M, 11% F |
| Race/ethnicity† | 49% W, 31% B, 18% H | 41% W, 32% B, 19% H | 42% W, 33% B, 22% H |
| Weight (kg) | 80 (69,88) | 77 (66,89) | 77(67,83) |
| Body Mass Index (kg/m ²) | 26 (23, 29) | 24 (22,28) | 24 (22, 27) |
| Concomitant Medications affecting Bone* | 22% | 22% | 20% |
| Current Smoking | 40% | 37% | 36% |
| CD4+ cell count (/mm ³) | 350 (211, 461) | 343 (207,461) | 355(207, 461) |
| HIV-1 RNA (log ₁₀ c/mL) | 4.62 (4.05, 5.10) | 4.52 (4.13, 5.08) | 4.52 (3.95, 4.95) |
| hsCRP (mg/L) | 1.45 (0.71, 3.16) | 1.35 (0.69, 2.8) | 1.17 (0.66, 2.95) |
| IL-6 (pg/mL) | 1.82 (1.20, 2.69) | 1.55 (1.07, 3.02) | 1.78 (1.20, 2.75) |
| sIL-2R (pg/ml) | 1862 (1479, 2291) | 1820 (1202, 2344) | 1660 (1202, 2239) |
| sCD14 (ng/ml) | 1778 (1413, 2138) | 1698 (1445, 1950) | 1660 (1445, 2042) |
| sCD163 (ng/ml) | 1148 (813, 1585) | 1230 (832, 1585) | 1023 (741, 1548) |
| OPG (pmol/L) | 3.89 (3.16, 4.90) | 3.98 (3.31, 4.68) | 4.47 (3.63, 5.25) |
| RANK L (pg/ml) | 35.5 (16.9, 58.9) | 26.9 (11.2, 53.7) | 24.5 (11.2, 49.0) |
| | N=101 | N=95 | N=101 |
| % CD4(+): CD28(-) CD57(+) | 4.8 (2.2, 9.9) | 5.2 (2.0, 11.3) | 5.3 (2.6, 9.3) |
| % CD4(+): CD28(-) CD57(+) PD1(+) | 0.03 (0.01, 0.07) | 0.03 (0.01, 0.07) | 0.03 (0.01, 0.06) |
| % CD8(+): CD28(-) CD57(+) | 23.0 (16.9, 30.5) | 25.9 (18.6, 30.9) | 22.9 (18.4, 30.5) |
| % CD8(+): CD28(-) CD57(+) PD1(+) | 0.07 (0.05, 0.12) | 0.08 (0.05, 0.16) | 0.09 (0.04, 0.14) |
| % CD4(+): CD38(+) HLADR(+) | 19.0 (11.9, 30.3) | 19.4 (12.0, 32.2) | 17.4 (10.3, 26.3) |
| % CD8(+): CD38(+) HLADR(+) | 41.7 (34.8, 55.2) | 44.7 (37.0, 53.7) | 42.5 (33.2, 53.2) |
| % MNC: CD14dimCD16+ | 0.7 (0.4, 1.7) | 0.7 (0.2, 1.9) | 0.9 (0.3, 1.6) |
| % MNC: CD14+CD16+ | 9.7 (5.9, 13.8) | 9.7 (5.0, 13.1) | 9.0 (5.7, 11.7) |

Values represent median (Q1,Q3) or percent; † W: white; B: black; H:hispanic; remaining represents other

*includes androgen, anticonvulsants, proton pump inhibitors, corticosteroids, estrogens, SSRIs

DOI: 10.1093/infdis/jiaa027

Erratum to: Repertoire and Neutralizing Activity of Antibodies Against Hepatitis C Virus E2 Peptide in Patients With Spontaneous Resolution of Hepatitis C

Anne Olbrich,¹ Hedda Wardemann,² Stephan Böhm,^{1,3} Karen Rother,¹ Che C. Colpitts,^{4,5} Florian Wensch,⁶ Thomas F. Baumert,⁶ Thomas Berg,^{1,a} and Julia Benckert^{1,4,a}

¹Laboratory for Clinical and Experimental Hepatology, Section of Hepatology, Clinic for Gastroenterology and Rheumatology, University Clinic Leipzig, Leipzig, Germany, ²Division of B Cell Immunology, German Cancer Research Center, Heidelberg, Germany, ³Max von Pettenkofer Institute, Munich, Germany, ⁴Inserm U1110, University of Strasbourg, France; ⁵Division of Infection and Immunity, University College London, United Kingdom; and ⁶Clinic for Hepatology and Gastroenterology, Charité, CVK, Berlin, Germany

In Repertoire and Neutralizing Activity of Antibodies Against Hepatitis C Virus E2 Peptide in Patients With Spontaneous Resolution of Hepatitis C [*J Infect Dis*, Volume 220, Issue 7, 1 October 2019, Pages 1209–1218, [https://](https://doi.org/10.1093/infdis/jiz274)

doi.org/10.1093/infdis/jiz274], the affiliations for authors Florian Wensch, Thomas F. Baumert, and Julia Benckert were incorrect. These have been updated in the article online.

DOI: 10.1093/infdis/jiaa052